Identification of Protein Signatures of Sjögren's Disease Activity and Their Modulation by Deucravacitinib in Anti-SSA Positive Patients with SLE: Results from a Phase 2 Study (ACR Convergence 2026) - Sep 8, 2026 - Abstract #2365; Pres time: Nov 10, 2026; 10:30 AM - 12:30 PM; Location: WB1&2; In Person; No abstract available
Clinical • P2 data • Inflammatory Arthritis • Sjogren's Syndrome
|